Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9903316 | 0.80 | GRM5 (0.43) | SLC6A2SLC6A4SLC6A3DRD2DRD4 | |
| SCHEMBL1992055 | 0.79 | APP (0.46) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24566036 | 0.75 | CYP19A1 (0.40) | SLC6A2SLC6A4SLC6A3DRD2DRD4 | |
| SCHEMBL1990213 | 0.74 | KIT (0.46) | — | |
| SCHEMBL6315893 | 0.74 | DYRK1A (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1306384 | 0.72 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1306505 | 0.70 | APP (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL12708991 | 0.70 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3DRD2DRD4 | |
| SCHEMBL30257827 | 0.69 | CDK2 (0.33) | — | |
| SCHEMBL29516544 | 0.69 | KIT (0.32) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152564-A1 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-05-15 | — | — | US | disclosed |
| WO-2025021218-A1 | CYSTAL FORM OF PROPENONE-CONTAINING BIOLOGICAL INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-119371440-A | Salt containing acrylketone biological inhibitor, salt crystal form, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-118574831-A | Biological inhibitor containing acrylketone, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| WO-2023143514-A1 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152564-A1 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CYP51A1, HSD17B7, CYP46A1 | SLC6A2 4570/4885SLC6A4 4360/4885SLC6A3 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.